3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Multiple Myeloma
232
Lymphoma
46
Lymphoma, Mantle-Cell
44
Neoplasms, Plasma Cell
40
Recurrence
30
Lymphoma, Non-Hodgkin
29
Lymphoma, Follicular
26
Leukemia, Myeloid, Acute
25
Lymphoma, Large B-Cell, Diffuse
22
Waldenstrom Macroglobulinemia
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Lymphoma, B-Cell, Marginal Zone
19
Leukemia, Lymphocytic, Chronic, B-Cell
19
Carcinoma, Non-Small-Cell Lung
18
Leukemia
15
Hodgkin Disease
13
Neoplasms
12
Immunoglobulin Light-chain Amyloidosis
12
Hematologic Neoplasms
11
Unspecified Adult Solid Tumor, Protocol Specific
9
Myelodysplastic Syndromes
9
Lymphoma, B-Cell
9
Burkitt Lymphoma
9
Lymphoma, Large-Cell, Immunoblastic
8
Lymphoma, Large-Cell, Anaplastic
8
Head and Neck Neoplasms
8
Congenital Abnormalities
8
Breast Neoplasms
8
Sarcoma
7
Lymphoma, Extranodal NK-T-Cell
7
Interventions
Nivolumab
2
trifluridine tipiracil drug combination
1
pembrolizumab
1
envafolimab
1
cobimetinib
1
TAK-981
1
Ipilimumab
1
Injections
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced or Metastatic Solid Tumors
×
Bortezomib
×
Clear all
NCT02220049
2016-03-25
VELDAY
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
Completed
18 enrolled